JCM Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by St. George, K.
Right arrow Articles by Landry, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by St. George, K.
Right arrow Articles by Landry, M. L.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, April 2000, p. 1430-1433, Vol. 38, No. 4
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

A Multisite Trial Comparing Two Cytomegalovirus (CMV) pp65 Antigenemia Test Kits, Biotest CMV Brite and Bartels/Argene CMV Antigenemia

Kirsten St. George,1 Molly J. Boyd,2 Steven M. Lipson,3 David Ferguson,4 G. Frank Cartmell,2 Leon H. Falk,3 Charles R. Rinaldo,1 and Marie L. Landry4,*

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania1; Integris Baptist Medical Center, Oklahoma City, Oklahoma2; North Shore University Hospital-NYU School of Medicine, Manhasset, New York3; and Yale University School of Medicine, New Haven, Connecticut4

Received 30 September 1999/Returned for modification 8 December 1999/Accepted 13 January 2000

A total of 513 blood specimens, predominantly from organ transplant recipients, human immunodeficiency virus-positive patients, and bone marrow transplant recipients, were tested for cytomegalovirus (CMV) by culture and pp65 antigenemia across four test sites. Peripheral blood leukocytes were examined by using both the Biotest CMV Brite and the Bartels/Argene CMV Antigenemia kits. A total of 109 specimens were positive for CMV, 106 (97%) were positive by antigenemia, and 34 (31%) were positive by culture. According to the manufacturers' instructions, 150,000 cells were applied per slide for the Biotest kit and 200,000 cells per slide for the Bartels kit. A total of 93 specimens (88%) were positive by the Biotest kit, and 86 (81%) were positive by the Bartels kit. In specimens found to be positive by only one kit, the positive cell counts were low (median, 1; range, 1 to 7). When the data from all four sites were combined and analyzed, there was no statistical difference between the performance of the two kits; the Biotest and Bartels kits were found to be equivalent in sensitivity, specificity, and positive and negative predictive values for the detection of CMV pp65 antigenemia.

* Corresponding author. Mailing address: Department of Laboratory Medicine, Yale University School of Medicine, P.O. Box 208035, New Haven, CT 06520-8035. Phone: (203) 688-3475. Fax: (203) 688-8177. E-mail: marie.landry{at}yale.edu.

Journal of Clinical Microbiology, April 2000, p. 1430-1433, Vol. 38, No. 4
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2000 by the American Society for Microbiology. All rights reserved.